The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Amarin disavows any obligation to update the information contained in such press releases after the date of their issuance.
Data Presented for Secondary and Exploratory Endpoint of Pivotal Study of AMR101 Includes Statistically Significant Reductions Compared to Placebo for Important Lipid Biomarkers
BEDMINSTER, N.J. and DUBLIN, Ireland , March 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, announced today that real-world data reported by the U.S. Veteran’s Administration supports that patients with
BEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 12/14/15 -- Amarin Corporation plc ( NASDAQ : AMRN) , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that it has been selected for addition to the NASDAQ
BEDMINSTER, N.J. , and DUBLIN, Ireland , Nov. 21, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that it has been selected for addition to the NASDAQ Biotechnology Index ® (Nasdaq:NBI), which
BEDMINSTER, NJ and DUBLIN, IRELAND , and MACAO S.A.R, PEOPLE'S REPUBLIC OF CHINA -- ( Marketwired ) -- 02/26/15 -- Amarin Corporation plc (NASDAQ: AMRN) and Eddingpharm, two pharmaceutical companies focused on the development and commercialization of innovative therapeutics, today announced an
Primary Endpoint and Overall Study Timing and Size Unchanged; Statistical Analysis Plan Finalized; Second Interim Efficacy Analysis and Additional Pre-Specified Endpoints Added
BEDMINSTER, N.J. , DUBLIN, Ireland , and TORONTO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and HLS Therapeutics Inc. ("HLS"), announced today an exclusive agreement between the parties to register, commercialize and distribute Vascepa® (icosapent ethyl) capsules in
BEDMINSTER, N.J. and DUBLIN, Ireland , June 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that it has entered into a multi-faceted
BEDMINSTER, NJ and DUBLIN, IRELAND -- ( Marketwired ) -- 04/08/15 -- Amarin Corporation, plc (NASDAQ: AMRN) and Walk with a Doc, a national nonprofit organization, today announced a 2015 partnership to expand the reach of their national health awareness efforts.